Raymed Labs Ltd - Stock Valuation and Financial Performance

BSE: 531207 | NSE: | Pharmaceuticals & Drugs | Small Cap

Raymed Labs Share Price

2.18 0.00 0.00%
as on 26-Mar'24 16:00

DeciZen - make an informed investing decision on Raymed Labs

M-Cap below 100cr DeciZen not available

Raymed Labs stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
0.9 Cr.
52-wk low:
2
52-wk high:
2.5

Is Raymed Labs Ltd an attractive stock to invest in?

1. Is Raymed Labs Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Raymed Labs Ltd is a below average quality company.

2. Is Raymed Labs Ltd undervalued or overvalued?

The key valuation ratios of Raymed Labs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Raymed Labs Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Raymed Labs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Raymed Labs:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Raymed Labs Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % -6.5%-7.1%-9%-17.9%-26.7%-35.9%-105.5%-94.4%8.1%7.7%-
Value Creation
Index
NANANANANANANANANANA-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 00000000000
Sales YoY Gr.-NANANANANANANANANA-
Adj EPS -0.1-0-0.1-0.1-0.1-0.1-0.1-0.2-0.2-0.4-0.3
YoY Gr.-NANANANANANANANANA-
BVPS (₹) -4-4.1-4.1-4.3-4.4-4.5-4.6-4.8-5-5.4-5.5
Adj Net
Profit
000000-0.1-0.1-0.1-0.20
Cash Flow from Ops. 0.10000000-2.2-0.2-
Debt/CF from Ops. 17-65.8370.524433.37705.31737.8-7238.47046.600-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NANANANA
Adj EPS NANANANA
BVPSNANANANA
Share Price -13.7% -1% 31.4% 6.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
1.41.11.31.921.72.93.43.97.75.7
Op. Profit
Mgn %
0000000000NAN
Net Profit
Mgn %
0000000000-INF
Debt to
Equity
-1.2-1.2-1.1-1.1-1.1-1-1-1.100-
Working Cap
Days
00000000000
Cash Conv.
Cycle
00000000000

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 5.70%

Sales growth has been subdued in last 3 years 0.00%

Sales growth is not so good in last 4 quarters at 0.00%

Latest Financials - Raymed Labs Ltd.

Standalone Consolidated
TTM EPS (₹) -0.3 -
TTM Sales (₹ Cr.) 0 -
BVPS (₹.) -5.5 -
Reserves (₹ Cr.) -7 -
P/BV -0.39 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 2.04 / 2.46
All Time Low / High (₹) 0.92 / 46.90
Market Cap (₹ Cr.) 0.9
Equity (₹ Cr.) 4.3
Face Value (₹) 10
Industry PE 47.8

Management X-Ray of Raymed Labs:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Raymed Labs

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales0000000000
Operating Expenses 0.030.040.030.030.030.030.060.070.080.19
Manufacturing Costs0000000000
Material Costs0000000000
Employee Cost 0.020.010.010.010.010.010.020.020.030.04
Other Costs 0.020.030.020.020.020.020.050.050.050.15
Operating Profit -0.03-0.04-0.03-0.03-0.03-0.03-0.06-0.07-0.08-0.19
Operating Profit Margin (%) ----------
Other Income 0.020.020.020.010.010.010.010.0100.02
Interest 0000000000
Depreciation 000.010.010.010.010.010.010.010.01
Exceptional Items -0.040-0.02-0.02-0.03-0.030000
Profit Before Tax -0.05-0.02-0.04-0.05-0.06-0.05-0.06-0.07-0.08-0.17
Tax 0000000000
Profit After Tax -0.05-0.02-0.04-0.05-0.06-0.05-0.06-0.07-0.08-0.17
PAT Margin (%) ----------
Adjusted EPS (₹)-0.10.0-0.1-0.1-0.1-0.1-0.1-0.2-0.2-0.4
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund -1.71-1.73-1.77-1.82-1.87-1.93-1.98-2.05-2.13-2.31
Share Capital 4.274.274.274.274.274.274.274.274.274.27
Reserves -5.99-6-6.04-6.09-6.15-6.20-6.26-6.33-6.41-6.58
Minority Interest0000000000
Debt1.9621.991.981.9922.022.1600
Long Term Debt0000000000
Short Term Debt1.9621.991.981.9922.022.1600
Trade Payables0000000000
Others Liabilities 0.050.040.060.120.160.190.220.142.382.46
Total Liabilities 0.300.300.280.280.270.260.260.250.250.16

Fixed Assets

Gross Block0.390.400.400.390.400.400.400.400.390.39
Accumulated Depreciation0.190.200.210.210.220.230.240.240.240.24
Net Fixed Assets0.200.200.190.190.180.170.170.160.160.15
CWIP 0000000000
Investments 0000000000
Inventories0000000000
Trade Receivables0.020.020.020.020.020.020.020.020.020
Cash Equivalents 0000000000
Others Assets0.070.070.060.070.070.070.060.060.060
Total Assets 0.300.300.280.280.270.260.260.250.250.16

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 0.12-0.030.0100000-2.21-0.16
PBT -0.05-0.02-0.04-0.05-0.06-0.05-0.06-0.07-0.08-0.17
Adjustment 000.010.010.010.010.010.010.010.07
Changes in Working Capital 0.16-0.010.030.040.050.050.050.06-2.13-0.06
Tax Paid 0000000000
Cash Flow From Investing Activity 0.0300000002.210.16
Capex 0.03000000000
Net Investments 0000000000
Others 000000002.210.16
Cash Flow From Financing Activity -0.180.03-0.010000000
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 0000000000
Interest Paid 0000000000
Dividend Paid 0000000000
Others -0.180.03-0.010000000
Net Cash Flow -0.04000000000
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
ROCE (%)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Asset Turnover Ratio0000000000
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days0000000000
Inventory Days0000000000
Payable Days0000000000

Raymed Labs Ltd Stock News

Raymed Labs Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Raymed Labs on 26-Mar-2024 16:00 is ₹2.18.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 26-Mar-2024 16:00 the market cap of Raymed Labs stood at ₹0.93.
The latest P/E ratio of Raymed Labs as of 26-Mar-2024 16:00 is 0.00.
The latest P/B ratio of Raymed Labs as of 26-Mar-2024 16:00 is -0.39.
The 52-week high of Raymed Labs is ₹2.46 and the 52-week low is ₹2.04.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Raymed Labs is ₹0.00 ( Cr.) .

About Raymed Labs Ltd

Raymed Labs was established in 1994 as a pharmaceutical company with emphasis on injectables with state of the art manufacturing facilities. the company is located at Dehradun Road, Saharanpur, UP. Manufacturing pharmaceutical products, as such, is a specialized job, however, manufacturing of injectables is even more difficult since they are normally given during a life saving situation thus their quality standards are much more stringent. Raymed’s quality quickly won the trusts of doctors and it established itself as one of the leading quality manufacturers of medicines in the area.

Raymed strives on a well organized management team of skilled and highly trained professionals from different streams.  This team contains chemists, pharmacists, marketing professionals with in-depth knowledge & requirements for human and animal products.

Products range:

  • RAMPICILLIN - Ampicillin, a semisynthetic penicillin
  • RAMPICLOX - Equal quantities of Ampicillin and Cloxacillin
  • RAMPIMOX - Equal quantities of Amoxycillin and Cloxacillin
  • RAMYKACIN - Amikacin Sulphate
  • OXYTETRACYCLINE - The most common Antibiotic in Veterinary Practice
  • RAMYFENAC-Diclofenac Sodium. It is a potent non steroidal Anti-inflammatory, Analgesic & Antipyretic for human use
  • RAMAMINE- Chlorpheniramine Maleate.  The most potent & effective Anti-histaminic for veterinary use
  • RAMYDEX-Dexamethasone Sodium Phosphate. Anti-inflammatory, Anti-allergic, Gluco-corticoid adjuvant with Antibiotic therapy
  • RAMYCIN-Gentamycin Sulphate
  • RAMYPINE - Atropin Sulphate.  The drug has anticholenergic effect in veterinary use.
  • RAMYCHLOR - Chloramphenicol
  • REALOPAR - Paracetamol
  • RAYVIL - Pheniramine Maleate
  • RAMALGIN-P - Phenylbutazone and Analgin with Lignocaine: A unique combination of highly effective analgesic, antispasmodic, anti-inflammatory & Antipyretic for veterinary use.
  • RAMYSCAB - Sulphur with Benzyl Benzoate in Lidocaine base: An ideal treatment of Scabies & other dermal problems in animals
  • RAMYVIT PLEX - Vitamin B1, Vitamin B2, Vitamin B3, Vitamin B12 with Liver Extract:  crude injection and ideal treatment of Scabies & other dermal problems in animals
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.